Safety, pharmacokinetics and efficacy of selumetinib in Chinese adult and paediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: The primary analysis of a phase 1 open-label study

Zhichao Wang; Xin Zhang; Chunyan Li; Yangbo Liu; Xiaoyun Ge; Jiajia Zhao; Xiaojun Yuan; Qingfeng Li

doi:10.1002/ctm2.1589

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (3) : e1589 DOI: 10.1002/ctm2.1589

LETTER TO THE JOURNAL

Safety, pharmacokinetics and efficacy of selumetinib in Chinese adult and paediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: The primary analysis of a phase 1 open-label study

Author information +

History +

PDF

Cite this article

Download citation ▾

Zhichao Wang, Xin Zhang, Chunyan Li, Yangbo Liu, Xiaoyun Ge, Jiajia Zhao, Xiaojun Yuan, Qingfeng Li. Safety, pharmacokinetics and efficacy of selumetinib in Chinese adult and paediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: The primary analysis of a phase 1 open-label study. Clinical and Translational Medicine, 2024, 14(3): e1589 DOI:10.1002/ctm2.1589

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Yap YS, McPherson JR, Ong CK, et al. The NF1 gene revisited—from bench to bedside. Oncotarget. 2014;5(15):5873-5892.

[2]	Bergqvist C, Servy A, Valeyrie-Allanore L, Ferkal S, Combemale P, Wolkenstein P. Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966. Orphanet J Rare Dis. 2020;15(1):37.

[3]	Blakeley JO, Plotkin SR. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Neuro Oncol. 2016;18(5):624-638.

[4]	Gross AM, Wolters PL, Dombi E, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med. 2020;382(15):1430-1442.

[5]	U.S. Food and Drug Administration. Selumetinib (Koselugo) Full Prescribing Information. Accessed January 5, 2024.

[6]	European Medicines Agency. Selumetinib (Koselugo) Summary of Product Characteristics. Accessed January 5, 2024.

[7]	AstraZeneca. Koselugo Approved in China for Paediatric Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas. Accessed January 5, 2024.

[8]	Dymond AW, Elks C, Martin P, et al. Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis. Eur J Clin Pharmacol. 2017;73(6):717-726.

[9]	Dombi E, Baldwin A, Marcus LJ, et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med. 2016;375(26):2550-2560.

[10]	Suenobu S, Terashima K, Akiyama M, et al. Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: an open-label, phase I study. Neurooncol Adv. 2023;5(1):vdad054.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.